Journal
NEURO-ONCOLOGY
Volume 20, Issue 2, Pages 192-202Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/nox119
Keywords
diacylglycerol kinase alpha; GBM subtypes; geranylgeranyltransferase I; mesenchymal phenotype; ritanserin
Categories
Funding
- National Institutes of Health [5R01CA180699, 1R01CA189524]
Ask authors/readers for more resources
The mesenchymal phenotype in glioblastoma (GBM) and other cancers drives aggressiveness and treatment resistance, leading to therapeutic failure and recurrence of disease. Currently, there is no successful treatment option available against the mesenchymal phenotype. We classified patient-derived GBM stem cell lines into 3 subtypes: proneural, mesenchymal, and other/classical. Each subtype's response to the inhibition of diacylglycerol kinase alpha (DGK alpha) was compared both in vitro and in vivo. RhoA activation, liposome binding, immunoblot, and kinase assays were utilized to elucidate the novel link between DGK alpha and geranylgeranyltransferase I (GGTase I). Here we show that inhibition of DGK alpha with a small-molecule inhibitor, ritanserin, or RNA interference preferentially targets the mesenchymal subtype of GBM. We show that the mesenchymal phenotype creates the sensitivity to DGK alpha inhibition; shifting GBM cells from the proneural to the mesenchymal subtype increases ritanserin activity, with similar effects in epithelial-mesenchymal transition models of lung and pancreatic carcinoma. This enhanced sensitivity of mesenchymal cancer cells to ritanserin is through inhibition of GGTase I and downstream mediators previously associated with the mesenchymal cancer phenotype, including RhoA and nuclear factor-kappaB. DGK alpha inhibition is synergistic with both radiation and imatinib, a drug preferentially affecting proneural GBM. Our findings demonstrate that a DGK alpha-GGTase I pathway can be targeted to combat the treatment-resistant mesenchymal cancer phenotype. Combining therapies with greater activity against each GBM subtype may represent a viable therapeutic option against GBM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available